TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) is now available.
Clarity Pharmaceuticals announced that data on its pan-cancer theranostic, 64/67Cu-SAR-bisFAP, will be presented at the World Molecular Imaging Conference 2025. The dual-targeting SAR-bisFAP has demonstrated superior tumor targeting and retention in pre-clinical studies, showing promise for future human clinical trials. This advancement could enhance Clarity’s position in the radiopharmaceutical industry and offer new treatment avenues for cancers with high unmet needs.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$5.70 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company specializing in the development of innovative Targeted Copper Theranostics for cancer treatment. Utilizing its SAR Technology Platform, Clarity aims to address serious diseases by improving treatment outcomes.
Average Trading Volume: 3,293,159
Technical Sentiment Signal: Buy
Current Market Cap: A$1.37B
For a thorough assessment of CU6 stock, go to TipRanks’ Stock Analysis page.